Abstract
Cord blood (CB) has been an alternative stem cell source for patients with a wide variety of hematological diseases. When compared with unrelated bone marrow transplantation (u-BMT), obvious advantages of CB are the rapid availability and tolerance of 2 HLA antigen mismatch, which have increased the chances of transplantation for patients who lack a suitable donor or need urgent transplantation. Although higher rates of engraftment failure as compared to other stem cell sources after cord blood transplantation (CBT) have been a serious concern, the mechanisms underlying these failures have gradually been clarified by analyzing accumulated clinical data, thereby contributing to improvement of engraftment. Recent large-scale retrospective comparisons of clinical outcomes between CBT and u-BMT from HLA-matched donors have obtained comparable results, and moreover, results of CBT have been promising even in elderly patients and those in non-remission status. This review describes the current status of CBT and problems to be solved, along with discussion of developing strategies aimed at improving patient outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
